[
  {
    "id": "GUIDE-001",
    "text_summary": "Lung-RADS v2022 is the ACR standardized reporting system for lung cancer screening CT. It categorizes findings from 1 (negative) to 4X (suspicious) to guide management recommendations.",
    "guideline_name": "ACR Lung-RADS v2022",
    "organization": "ACR",
    "year": 2022,
    "modality": "ct",
    "body_region": "chest",
    "clinical_indication": "Lung cancer screening in high-risk adults",
    "classification_system": "Lung-RADS",
    "key_recommendation": "Category 1-2: continue annual screening. Category 3: 6-month LDCT. Category 4A: 3-month LDCT or PET/CT. Category 4B/4X: tissue sampling or PET/CT and chest CT.",
    "evidence_level": "validated"
  },
  {
    "id": "GUIDE-002",
    "text_summary": "BI-RADS 5th edition provides a standardized lexicon and reporting system for mammography, ultrasound, and MRI of the breast. Categories 0-6 guide management from additional imaging to biopsy.",
    "guideline_name": "ACR BI-RADS 5th Edition",
    "organization": "ACR",
    "year": 2013,
    "modality": "mammography",
    "body_region": "breast",
    "clinical_indication": "Breast cancer screening and diagnostic evaluation",
    "classification_system": "BI-RADS",
    "key_recommendation": "Category 0: incomplete, need additional imaging. Category 1-2: negative/benign, routine screening. Category 3: probably benign, 6-month follow-up. Category 4-5: suspicious/highly suspicious, biopsy recommended. Category 6: known malignancy.",
    "evidence_level": "validated"
  },
  {
    "id": "GUIDE-003",
    "text_summary": "ACR TI-RADS is a point-based risk stratification system for thyroid nodules on ultrasound. Points are assigned based on composition, echogenicity, shape, margin, and echogenic foci.",
    "guideline_name": "ACR Thyroid Imaging Reporting and Data System (TI-RADS)",
    "organization": "ACR",
    "year": 2017,
    "modality": "ultrasound",
    "body_region": "neck",
    "clinical_indication": "Thyroid nodule evaluation and management",
    "classification_system": "TI-RADS",
    "key_recommendation": "TR1 (benign): no FNA. TR2 (not suspicious): no FNA. TR3 (mildly suspicious): FNA if >= 2.5cm. TR4 (moderately suspicious): FNA if >= 1.5cm. TR5 (highly suspicious): FNA if >= 1.0cm.",
    "evidence_level": "validated"
  },
  {
    "id": "GUIDE-004",
    "text_summary": "LI-RADS is the ACR standardized system for reporting liver observations in patients at risk for hepatocellular carcinoma. It uses imaging features on CT and MRI to assign categories from LR-1 (definitely benign) to LR-5 (definitely HCC).",
    "guideline_name": "ACR Liver Imaging Reporting and Data System (LI-RADS)",
    "organization": "ACR",
    "year": 2018,
    "modality": "ct",
    "body_region": "abdomen",
    "clinical_indication": "Hepatocellular carcinoma surveillance in cirrhosis or chronic hepatitis B",
    "classification_system": "LI-RADS",
    "key_recommendation": "LR-1/2: benign, continue surveillance. LR-3: intermediate probability, follow-up in 3-6 months. LR-4: probable HCC, consider multidisciplinary discussion. LR-5: definite HCC, treat without biopsy. LR-M: probably malignant, not HCC specific.",
    "evidence_level": "validated"
  },
  {
    "id": "GUIDE-005",
    "text_summary": "The 2017 Fleischner Society guidelines provide recommendations for management of incidental pulmonary nodules detected on CT, stratified by nodule size, type, and patient risk factors.",
    "guideline_name": "Fleischner Society 2017 Pulmonary Nodule Guidelines",
    "organization": "Fleischner Society",
    "year": 2017,
    "modality": "ct",
    "body_region": "chest",
    "clinical_indication": "Incidental pulmonary nodule management in adults (not lung cancer screening)",
    "classification_system": "Fleischner",
    "key_recommendation": "Solid nodule <6mm (low risk): no follow-up. 6-8mm (low risk): CT at 6-12 months. 6-8mm (high risk): CT at 6-12 months, then 18-24 months. >8mm: CT at 3 months, PET/CT, or biopsy. Ground-glass: >6mm follow-up at 6-12 months.",
    "evidence_level": "validated"
  },
  {
    "id": "GUIDE-006",
    "text_summary": "The 2017 McDonald Criteria provide revised diagnostic criteria for multiple sclerosis incorporating MRI findings of dissemination in space (DIS) and dissemination in time (DIT) across the CNS.",
    "guideline_name": "McDonald Criteria 2017 (Multiple Sclerosis)",
    "organization": "International Panel on Diagnosis of MS",
    "year": 2017,
    "modality": "mri",
    "body_region": "brain",
    "clinical_indication": "Diagnosis of multiple sclerosis and clinically isolated syndrome",
    "classification_system": "McDonald Criteria",
    "key_recommendation": "DIS: 1+ T2 lesions in 2+ of 4 areas (periventricular, cortical/juxtacortical, infratentorial, spinal cord). DIT: simultaneous enhancing and non-enhancing lesions, or new T2/enhancing lesion on follow-up. CSF oligoclonal bands can substitute for DIT.",
    "evidence_level": "validated"
  },
  {
    "id": "GUIDE-007",
    "text_summary": "Brain Trauma Foundation guidelines for surgical management of traumatic intracranial hemorrhage, including epidural hematoma, acute subdural hematoma, and intraparenchymal hemorrhage.",
    "guideline_name": "Brain Trauma Foundation Guidelines (ICH Management)",
    "organization": "Brain Trauma Foundation",
    "year": 2020,
    "modality": "ct",
    "body_region": "head",
    "clinical_indication": "Surgical management of traumatic brain injury and intracranial hemorrhage",
    "classification_system": "GCS/ICH Score",
    "key_recommendation": "EDH >30mL: surgical evacuation regardless of GCS. Acute SDH >10mm thickness or >5mm midline shift: surgical evacuation. ICH with GCS 6-8 and lobar clot >30mL within 1cm of cortex: consider evacuation. ICP monitoring for GCS <=8.",
    "evidence_level": "validated"
  },
  {
    "id": "GUIDE-008",
    "text_summary": "RECIST 1.1 provides standardized criteria for assessing tumor response to therapy using CT and MRI measurements. It defines complete response, partial response, stable disease, and progressive disease.",
    "guideline_name": "RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)",
    "organization": "EORTC/NCI/NCIC",
    "year": 2009,
    "modality": "ct",
    "body_region": "whole_body",
    "clinical_indication": "Assessment of solid tumor response to therapy in clinical trials and practice",
    "classification_system": "RECIST",
    "key_recommendation": "Measure up to 5 target lesions (max 2 per organ), sum longest diameters. CR: disappearance of all target lesions. PR: >=30% decrease. PD: >=20% increase (minimum 5mm absolute). SD: neither PR nor PD criteria met.",
    "evidence_level": "validated"
  },
  {
    "id": "GUIDE-009",
    "text_summary": "ATS/ERS guidelines for diagnosis of idiopathic interstitial pneumonias classify ILD patterns on HRCT and provide diagnostic criteria for UIP, NSIP, and other subtypes.",
    "guideline_name": "ATS/ERS Classification of Idiopathic Interstitial Pneumonias",
    "organization": "ATS/ERS",
    "year": 2013,
    "modality": "ct",
    "body_region": "chest",
    "clinical_indication": "Diagnosis and classification of interstitial lung disease",
    "classification_system": "ATS/ERS IIP Classification",
    "key_recommendation": "Definite UIP pattern on HRCT: subpleural, basal-predominant honeycombing with traction bronchiectasis, no features suggesting alternative diagnosis. Definite UIP pattern on HRCT may obviate surgical lung biopsy for IPF diagnosis.",
    "evidence_level": "validated"
  },
  {
    "id": "GUIDE-010",
    "text_summary": "ACR Appropriateness Criteria for Head Trauma provide evidence-based guidelines for selecting the most appropriate initial imaging study based on clinical presentation and risk stratification.",
    "guideline_name": "ACR Appropriateness Criteria: Head Trauma",
    "organization": "ACR",
    "year": 2020,
    "modality": "ct",
    "body_region": "head",
    "clinical_indication": "Initial imaging evaluation of acute head trauma",
    "classification_system": "ACR Appropriateness Criteria",
    "key_recommendation": "CT head without contrast is the initial study of choice for moderate-to-severe head trauma (GCS <=12). For mild TBI with risk factors (anticoagulation, age >65, focal deficit), CT head indicated. Low-risk mild TBI: clinical observation may suffice.",
    "evidence_level": "validated"
  },
  {
    "id": "GUIDE-011",
    "text_summary": "The Bosniak Classification v2019 provides a standardized system for categorizing renal cystic masses on CT and MRI to predict malignancy risk and guide management.",
    "guideline_name": "Bosniak Classification of Renal Cystic Masses v2019",
    "organization": "Bosniak Classification Working Group",
    "year": 2019,
    "modality": "ct",
    "body_region": "abdomen",
    "clinical_indication": "Classification and management of incidentally detected cystic renal masses",
    "classification_system": "Bosniak",
    "key_recommendation": "Class I: simple cyst, benign, no follow-up. Class II: minimally complex, benign, no follow-up. Class IIF: mildly complex, follow-up imaging. Class III: indeterminate, 50% malignancy rate, surgery or active surveillance. Class IV: clearly malignant, surgical excision.",
    "evidence_level": "validated"
  },
  {
    "id": "GUIDE-012",
    "text_summary": "RANO Criteria provide standardized response assessment criteria for brain tumors on MRI, incorporating enhancing tumor, non-enhancing FLAIR abnormality, and clinical status.",
    "guideline_name": "RANO Criteria (Response Assessment in Neuro-Oncology)",
    "organization": "RANO Working Group",
    "year": 2010,
    "modality": "mri",
    "body_region": "brain",
    "clinical_indication": "Response assessment of brain tumors (gliomas) to therapy",
    "classification_system": "RANO",
    "key_recommendation": "CR: complete disappearance of all enhancing disease, stable/improved T2/FLAIR. PR: >=50% decrease in enhancing disease. PD: >=25% increase in enhancing disease or new lesion. SD: all other situations. Pseudoprogression must be considered within 12 weeks of chemoradiation.",
    "evidence_level": "validated"
  }
]
